248 related articles for article (PubMed ID: 22752426)
1. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Mizuma M; Rasheed ZA; Yabuuchi S; Omura N; Campbell NR; de Wilde RF; De Oliveira E; Zhang Q; Puig O; Matsui W; Hidalgo M; Maitra A; Rajeshkumar NV
Mol Cancer Ther; 2012 Sep; 11(9):1999-2009. PubMed ID: 22752426
[TBL] [Abstract][Full Text] [Related]
2. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
3. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
Cook N; Frese KK; Bapiro TE; Jacobetz MA; Gopinathan A; Miller JL; Rao SS; Demuth T; Howat WJ; Jodrell DI; Tuveson DA
J Exp Med; 2012 Mar; 209(3):437-44. PubMed ID: 22351932
[TBL] [Abstract][Full Text] [Related]
4. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.
Plentz R; Park JS; Rhim AD; Abravanel D; Hezel AF; Sharma SV; Gurumurthy S; Deshpande V; Kenific C; Settleman J; Majumder PK; Stanger BZ; Bardeesy N
Gastroenterology; 2009 May; 136(5):1741-9.e6. PubMed ID: 19208345
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
8. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Timme CR; Gruidl M; Yeatman TJ
Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
[TBL] [Abstract][Full Text] [Related]
9. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
10. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
11. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
12. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
13. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
Zhuang Z; Ju HQ; Aguilar M; Gocho T; Li H; Iida T; Lee H; Fan X; Zhou H; Ling J; Li Z; Fu J; Wu M; Li M; Melisi D; Iwakura Y; Xu K; Fleming JB; Chiao PJ
Clin Cancer Res; 2016 Mar; 22(6):1432-44. PubMed ID: 26500238
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
16. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
17. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
18. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.
Palagani V; El Khatib M; Kossatz U; Bozko P; Müller MR; Manns MP; Krech T; Malek NP; Plentz RR
PLoS One; 2012; 7(10):e46514. PubMed ID: 23094026
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
